A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal lesions.

Abbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The decision to discontinue the study is not related to any safety concern. The rationale for this proposal is based on the following considerations:

The performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and no stent fractures, and the rate of additional revascularizations has been stable since approximately 14 months after the procedure.

Evaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature show low rates of death, reintervention and stent fracture, which are consistent with STRIDES and demonstrate the safety of the nitinol stent platform of the DYNALINK-E.

Long-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E - everolimus tissue concentration drops below the quantifiable limit by approximately 17 months after implant, and vascular response to the coating is normal with widely patent lumens and struts incorporated into vessel tissue.

The safety and performance of the DYNALINK-E has been substantiated by its clinical and pre-clinical data, and by the clinical data of similar products. Given the demonstrated mechanical integrity of the stent along with the evidence of a healthy long-term vascular response, there is a reasonable expectation of continued low event rates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease

NCT06410313

Superficial Femoral Artery Stenosis Popliteal Artery Stenosis

RECRUITING NA

Drug Eluting Stents In The Critically Ischemic Lower Leg 2

NCT01442636

Peripheral Arterial Disease

COMPLETED PHASE2/PHASE3

The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial

NCT00217256

Coronary Artery Disease

COMPLETED NA

Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery

NCT01396525

Peripheral Vascular Disease

COMPLETED PHASE3

Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population

NCT01556126

Stable Angina Unstable Angina Acute Myocardial Infarction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, Non-Randomized, Single-arm, Multi-center, Clinical Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for the Treatment of Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis Peripheral Vascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.

Group Type OTHER

Dynalink®-E everolimus-eluting peripheral stent

Intervention Type DEVICE

Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

Dynalink®-E, everolimus-eluting peripheral stent

Intervention Type DEVICE

Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dynalink®-E everolimus-eluting peripheral stent

Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

Intervention Type DEVICE

Dynalink®-E, everolimus-eluting peripheral stent

Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rutherford Becker Category 2-5
* Single de novo or restenotic lesion in the superficial femoral or proximal popliteal artery
* Disease segment length 30-170 mm
* \>50% diameter stenosis or total occlusion
* Target reference vessel diameter 4.3-7.3 mm

Exclusion Criteria

* Target lesion previously treated with stent or surgery
* Rutherford Becker Category 0, 1, or 6
* Immunosuppressive disorder or currently receiving immunosuppressive agents
* Serum creatinine \>2.5 mg/dl

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No